Reduction of triglyceride levels (TG lowering)

Reduction of triglyceride levels is a clinical endpoint and therapeutic goal in the management of hypertriglyceridemia, rather than a single molecular target. It represents the physiological result of interventions that modulate lipid metabolism, typically through the regulation of triglyceride-rich lipoproteins (TRLs) such as chylomicrons and very-low-density lipoproteins [1, 5, 13]. While this is a hallmark of therapeutic efficacy, the actual molecular targets used to achieve this effect include Peroxisome proliferator-activated receptor alpha (PPAR-alpha), Apolipoprotein C-III (ApoC-III), and Angiopoietin-like protein 3 (ANGPTL3) [2, 16]. Decreasing these levels is critical for reducing the risk of acute pancreatitis in patients with severe elevations (>500 mg/dL) and managing residual cardiovascular risk in patients with dyslipidemia [4, 10, 18]. Pharmacological agents such as fibrates, omega-3 fatty acids, and novel antisense oligonucleotides facilitate this outcome by enhancing lipoprotein lipase (LPL) activity or reducing hepatic VLDL production [2, 9, 12]. Thus, while 'reduction of triglyceride levels' is the desired outcome, it is achieved through the coordinated modulation of specific enzymes, receptors, and apolipoproteins involved in lipid transport and hydrolysis [10, 15].

Other names

Triglyceride loweringTriglyceride reductionLipid loweringSerum triglyceride managementHypertriglyceridemia treatment

Activation of Peroxisome proliferator-activated receptor alpha (PPAR-alpha) to increase fatty acid oxidation, inhibition of Apolipoprotein C-III (ApoC-III) to enhance lipoprotein lipase (LPL) activity, and inhibition of Angiopoietin-like 3 (ANGPTL3) to promote triglyceride-rich lipoprotein clearance.